
USSN10/050,279
Office action dated 22 Mar 2003
Response dated 25 Mar 2004



In the Restriction action issued 28 Jan 2004, a restriction requirement was raised between group I, drawn to method claims, and group II, drawn to a non-human organism. Claim group I, drawn to claims 1-20, 23-42, 45-63 and 66-84, and cancel non-elected claims 21-22, 43-44, 64-65 and 85-86 without prejudice to their renewal in a subsequently filed application.

In response to the requirement to elect an embodiment for the protein of interest, Applicants elect the antibody of claim 3. The species of antibody elected is IgG (claim 5).

In response to the requirement to elect an embodiment for the cell surface capture molecule, Applicants elect the antibody-binding protein of claim 7. The species of antibody-binding protein elected is an Fc receptor (claim 9).

Conclusion

It is believed that this document is now fully responsive to the Restriction requirement raised in the Restriction action dated 28 January 2004. In light of the above amendments and remarks, it is believed that the claims are now in condition for allowance, and such action is respectfully urged.

Fees

Although it is believed that no fees are due, in the event the Patent Office determines that fees are due, the Commissioner is hereby authorized to charge Deposit Account Number 18-050 in the amount of any fees deemed to be due.

Respectfully submitted

Valeta Gregg, Ph.D., Reg. No. 35,12

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591

(914) 345-7400